Department of Hematology-Oncology, The University of Texas Health Science Center at Houston, 6431 Fannin Street, Huston, TX 77030, USA.
Int J Mol Sci. 2022 Oct 5;23(19):11836. doi: 10.3390/ijms231911836.
Blast crisis (BC) is one of the most dreaded complications of chronic myeloid leukemia (CML). Fortunately, the incidence of BC has diminished markedly in the tyrosine kinase inhibitor (TKI) era. The primary objective of initial treatment in BC is to achieve a second chronic phase (CP) and to proceed to an allogeneic stem cell transplantation (SCT) in eligible patients. The clinical outcome of patients with CML BC remains unsatisfactory, even with highly potent TKIs, as remissions are short lived and there is an unmet need for novel therapies. We provide a comprehensive summary reviewing the current management of Lymphoid BC.
急变期（BC）是慢性髓细胞白血病（CML）最可怕的并发症之一。幸运的是，在酪氨酸激酶抑制剂（TKI）时代，BC 的发病率已显著降低。BC 初始治疗的主要目标是实现第二次慢性期（CP），并在符合条件的患者中进行异基因干细胞移植（SCT）。即使使用高效 TKI，CML BC 患者的临床结果仍不尽如人意，因为缓解期短暂，且需要新型疗法。我们提供了一份全面的综述，回顾了淋巴母细胞性 BC 的当前治疗管理。
